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Summary
A tumor-supporting role for the TNF-like ligand APRIL has been suggested. Here we describe that 9- to 12-month-old
APRIL transgenic mice develop lymphoid tumors that originate from expansion of the peritoneal B-1 B cell population. Aging
APRIL transgenic mice develop progressive hyperplasia in mesenteric lymph nodes and Peyer’s patches, disorganization of
affected lymphoid tissues, mucosal and capsular infiltration, and eventual tumor cell infiltration into nonlymphoid tissues
such as kidney and liver. We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia
(B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may
provide a therapeutic strategy to treat B-CLL patients.
Introduction cyte expansion in the peritoneum and is reminiscent of human
B-CLL.
APRIL (a proliferation-inducing ligand) is a secreted protein,
named for its capacity to stimulate tumor cell proliferation in vitro Results and discussion
(Medema et al., 2003). APRIL mRNA is expressed in hematopoi-
etic cells, and the protein has been detected in primary T cells B-CLL, the most prevalent leukemia in Western countries, is
characterized by gradual accumulation of CD5 B cells, due toand dendritic cells (Litinskiy et al., 2002; Pradet-Balade et al.,
2002). APRIL transcripts are also observed in a variety of nonhe- a survival advantage (Bannerji and Byrd, 2000; Keating, 1999).
Novak et al. showed that transcripts of the TNF family membermatopoietic carcinoma lines and primary tumor samples, point-
ing to APRIL involvement in tumor formation and/or mainte- BAFF (BLyS) (Mackay et al., 2002), a fundamental survival factor
for transitional and mature B cells, are expressed aberrantly innance (Deshayes et al., 2004; Hahne et al., 1998; Kelly et al.,
2000; Novak et al., 2002; Rennert et al., 2000). Concurring with B-CLL cells (Novak et al., 2002). In addition, APRIL mRNA was
detected in a small percentage (10%) of B-CLL samples ana-this, APRIL-transfected NIH-3T3 fibroblasts show an increased
tumor growth rate in nude mice (Hahne et al., 1998; Rennert et lyzed, leading to the conclusion that BAFF, and possibly APRIL,
is involved in B-CLL development (Novak et al., 2002). Thisal., 2000). Moreover, sequestering APRIL with a soluble form
of B cell maturation antigen (BCMA-Fc), an APRIL receptor, study was recently extended by Kern et al., who found BAFF
and APRIL expression in all B-CLL samples tested, at levelsretards growth of colon and lung carcinomas that express APRIL
endogenously (Rennert et al., 2000), supporting the idea that comparable to those detected in normal B cells (Kern et al., 2004).
To corroborate these findings, we analyzed a panel of B-CLLAPRIL has an important role in tumor growth. We provide com-
pelling evidence that APRIL promotes tumor formation, as tumors and found that 18 of 40 B-CLL samples expressed
detectable amounts of APRIL mRNA (Figure 1A and results notAPRIL transgenic (Tg) mice develop lymph node hyperplasia
after 9 months of age. Hyperplasia is initiated by B-1 B lympho- shown). APRIL mRNA levels were not derived from contaminat-
S I G N I F I C A N C E
A gradual accumulation of CD5 B cells resulting from an elevated survival capacity is characteristic for B-CLL, the most common
leukemia in Western countries. The underlying mechanisms that cause B-CLL are mostly unknown. Here we report the development
of B-1 cell-associated tumor formation in aging APRIL transgenic mice being highly reminiscent of human B-CLL. Increased APRIL
mRNA and serum levels in samples of B-CLL patients strongly suggest an implication of this cytokine in B-CLL. We therefore propose
that APRIL transgenic mice are an appropriate animal model for studying the human disease.
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CD23, and CD5) as well as B-1 cells (CD43, IgD, lowIgMhigh,
B220low, and CD23) (Berland and Wortis, 2002). The B-1 popu-
lation can be further divided into B-1a and B-1b cells, based
on CD5 expression, which is present in B-1a and not in B-1b
cells (Berland and Wortis, 2002). As reported (Stein et al., 2002),
no change in the B-1/B-2 cell ratio was detected in the peritoneal
exudate cells (PEC) of APRIL-Tg mice at 6–12 weeks of age.
Analysis of older mice (9–12 months) nonetheless revealed that
B-1 cells were present in a significantly higher percentage in
the PEC of APRIL-Tg mice than in the ones of littermates (Figure
2A). Importantly, cellular expansion is specific for peritoneal B-1
B cells, as no effect on splenic B cell populations is observed
(Table 1). Moreover, serum IgA levels, a typical sign of B-1 cell
activity, are significantly increased in older APRIL-Tg mice, thus
concurring with a recent report on defective IgA production in
APRIL/ mice (Castigli et al., 2004) (Figure 2B). Most B-1 cells
in the peritoneum of older Tg mice express CD5, indicatingFigure 1. Elevated APRIL levels in B-CLL tumor samples and patient serum
that the expanding population is comprised of B-1a cells, thusA: PCR analysis using RNA derived from 12 B-CLL patients. Upper panel
reminiscent of the cells detected in B-CLL patients. At an inter-shows APRIL, lower panel shows  actin control. Picture is representative of
40 samples analyzed. Control B cell samples are derived by magnetic cell mediate age (4–5 months), enlargement of the B-1 cell pool was
sorting from pooled buffy coats from at least 5 donors. already evident in the APRIL-Tg mouse peritoneum (Figure 2A),
B: B-CLL cells were purified to near-homogeneity (98%) by magnetic sort- suggesting that these cells accumulate slowly over time. Indeed,
ing and reanalyzed for APRIL mRNA expression. Sample numbers are identi-
scoring the mice for B-1 expansion in different age groups (9–12,cal to A.
13–15, 15 months) revealed that B-1 expansion gradually af-C: Serum APRIL levels in normal healthy donors (n  12) and B-CLL patients
(n  22) as determined by ELISA. fects all Tg mice and increases in severity over time (Figure 2F).
Closer inspection of 9- to 12-month-old APRIL-Tg mice
showed significant lymphoid organ alterations, i.e., in either
mesenteric lymph nodes (mLN) or Peyer’s patches (PP), in about
ing cells in the B-CLL preparations (Figure 1B), nor was APRIL 40% of animals analyzed. We found marked enlargement of
mRNA detectable in naı¨ve B cells under these conditions, indi- mLN (Figure 2C), which was due to an increase in cell number
cating that a large fraction of B-CLL tumors overexpress APRIL (Figure 2D). No alterations in mLN were observed in age-
mRNA (Figure 1A). As APRIL acts as a secreted cytokine (Lopez- matched littermates or in an APRIL-Tg line that lacks detectable
Fraga et al., 2001), we used ELISA to determine whether B-CLL transgene protein expression (Figure 2D) (Stein et al., 2002),
patients have increased circulating APRIL levels, comparing demonstrating that expansion depends on transgenic APRIL
sera from patients and healthy donors. This analysis revealed expression. In addition to mLN, PP in APRIL-Tg mice were
a significant increase in serum APRIL levels in a patient cohort larger on average than those of littermates (Figures 2C–2E).
(Figure 1C). Our data therefore indicate that this cytokine is Examination of 40 paraffin-embedded PP derived from 13 older
overexpressed in a large fraction of B-CLL tumors, resulting in APRIL-Tg mice (3 PP/mouse) revealed that 7 PP (from 5 differ-
increased APRIL serum levels in B-CLL patients. ent mice) measured from 25 mm2 to 122.6 mm2, which is larger
New Zealand White mice are often used as a model for than the maximum PP size in littermates (Figure 2E). Increased
B-CLL, as they show massive expansion of CD5 B cells (also PP size was paralleled by an increase in cell numbers in these
termed B-1 B cells [B-1 cells]) in older age (Hamano et al., 1998). organs (not shown). In extreme cases, PP and mLN were ap-
Similarly, transgenic mice containing B-cell specific expression proximately 10-fold larger than their counterparts in littermates
of the T cell leukemia-1 (TCL1) gene, an oncogene translocated (Figure 2C–2E). Also, for the mLN and PP alterations, we found
in some human T cell leukemia, develop B-CLL-like characteris- that incidence and severity increase over time (Figure 2F), sug-
tics due to CD5 B cell expansion (Bichi et al., 2002). Thus, gesting a progressive hyperplasia.
murine models for B-CLL depend on the expansion of B-1 B Spleen hyperplasia was also detected in older APRIL-Tg
cells. Physiologically, these cells play an important role in T cell- mice with increasing incidence during aging (Figure 2F). Spleen
independent humoral responses, and a large proportion of these architecture was highly disorganized, such that red and white
cells reside in the peritoneal cavity (Berland and Wortis, 2002). pulp areas became indistinguishable (Figure 3A). Similar disrup-
tion of T and B cell-rich areas was also observed in enlargedWe recently showed that APRIL-Tg mice, which have detectable
APRIL protein levels in serum, show significantly elevated type 1 mLN of APRIL-Tg mice (Figure 3B). Cell infiltration, as seen in
malignancy (Frederickson and Harris, 2000), was detectableand type 2 thymus-independent (TI) humoral immune responses
(Stein et al., 2002) (M.H., unpublished data), suggesting that in the capsule of hyperplasic spleen (Figure 3A) and in the
subcapsular sinus of mLN (Figure 3C), as well as in PP, asB-1 cell activity is promoted by APRIL. In addition, serum IgM
concentrations in APRIL-Tg mice are increased approximately determined by the large B cell numbers within the lamina propria
of the intestinal mucosa. Nevertheless, epithelial layer destruc-2-fold compared to control littermates (Stein et al., 2002), proba-
bly a consequence of increased B-1 cell activity in the Tg mice tion was not seen (Figure 3D).
Although unaffected mLN and PP of 9-month-old APRIL-(Potter and Melchers, 2000).
The lymphoid population in the peritoneal cavity consists Tg mice revealed no significant alteration in either T cell or B
cell composition in comparison with age-matched littermatesmainly of B-2 B cells or mature B cells (IgDhigh, CD43, IgM, B220,
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Figure 2. B-1 cell expansion, hyperplasia in
lymphoid organs, and kidney alterations in aging
APRIL-Tg mice
A: Peritoneal cells were isolated, and the B-1:B-2
cell ratio was determined at different ages and
compared between control littermates and
APRIL-Tg mice. B-1 cells were identified by CD5,
CD23, CD43, IgD, IgM,and B220 cell surface
staining. Representative images are shown of 10
mice analyzed.
B: IgA levels in older (9 months) APRIL-Tg and
littermates (n  10) was determined in the sera
using a commercially available ELISA kit.
C: Images of mLN and PP with advanced hyper-
plasia taken from a 15-month-old APRIL-Tg
mouse and an age-matched littermate.
D: Hyperplasia in APRIL-Tg mouse mLN. Cell num-
bers were determined in 9- to 12-month-old
APRIL-Tg mice, line 3919 (black circles) express-
ing the transgenic protein, line 2968 (gray cir-
cles), which do not express the transgenic pro-
tein (Stein et al., 2002), and control littermates
(open circles).
E: Comparison of PP size, determined by measur-
ing paraffin-embedded organs, in control lit-
termates (white bars, n  29) and APRIL-Tg mice
(black bars, n  40). Dotted line indicates maxi-
mum PP size measured in controls.
F: Incidence of hyperplasia in older APRIL-Tg
mice. PEC B-1 expansion, mLN, PP, and spleen
hyperplasia, and kidney infiltration were deter-
mined in three APRIL-Tg mouse age groups (9–12
months, 12–15 months, and 15 months). Mice
(20–45/group) were analyzed, and the total
number for each group was established as 100%.
For PEC (left panel), an increase in B-1 cells up
to 50% is considered mild (light gray bars),
whereas 50% increase is considered severe
(dark gray bars). For mLN, PP, and spleen, the
mild phenotype (light gray bars) represents a 2-
to 3-fold increase in cellularity; a severe pheno-
type is defined as a 3-fold increase (dark gray
bars). Kidney infiltration is considered severe at
all times, as no lymphocytes are normally pres-
ent. Statistical significance is indicated, as deter-
mined by ANOVA.
(not shown), the relative mLN composition of hyperplasic mLN reflects cell size and can be a measure for activation, showed
accumulation of enlarged blast-like cells (Figure 3E) in both Twas moderately affected. That is, B220 cell percentages were
slightly increased (35.5  2.6% versus 47.7  8%, p  0.005), and B populations (not shown). Concomitant with this pheno-
type, we observed that both CD4 and CD8 T cells in enlargedCD4 cell percentages were unaffected (34.0  1.9% versus
34.4  5%, p  0.05), and CD8 cell percentages were slightly mLN showed characteristic signs of activation, including down-
regulation of CD3 and CD45RB (not shown). Specifically, wedecreased (28.4  2.7% versus 18.3  2.7%, p  0.005). De-
spite these changes in the relative numbers of lymphoid popula- found an increase in CD62L CD44 effector T cells (Figure
3F), while B220 B cells displayed increased CD80 and CD86tions, the absolute number of CD4, CD8, and B220 cells
had increased, as the mLN and PP cellularity increased more levels, pointing to B cell activation (Figure 3F). All these popula-
tions showed a large proportion of mitotically active cells, asthan 2-fold. Thus, B and T cell populations had all expanded in
enlarged mLN from Tg mice. Forward/side scatter analysis, which determined by staining for the mitosis-associated protein Ki-67
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Table 1. Ectopic APRIL expression does not influence splenocyte development in 9-month-old APRIL Tg mice
Control littermate APRIL Tg
Cell number  106 S.D. Cell number  106 S.D. p value
splenocytes 80.6 (100%) 1.5 79.4 (100%) 3.2 p  0.05
B cells 45.5 (56.3%) 2.5 43.2 (54.4%) 3.1 p  0.05
mature B cells 29.7 (36.8%) 4.9 27.9 (35.2%) 3.0 p  0.05
MZ B cells 2.5 (3.1%) 0.4 2.2 (2.8%) 0.4 p  0.05
T1 B cells 2.6 (3.2%) 1.5 2.9 (3.7%) 0.7 p  0.05
T2 B cells 7.4 (9.2%) 0.9 6.6 (8.3%) 1.2 p  0.05
B1 cells 3.3 (4.1%) 0.7 4.1 (5.1%) 1.1 p  0.05
macrophages 1.8 (2.2%) 0.7 3.4 (4.3%) 1.0 p  0.05
granulocytes* 3.4 (4.2%) 1.0 3.0 (3.8%) 0.8 p  0.05
dendritic cells 1.8 (2.2%) 0.1 2.0 (2.5%) 0.5 p  0.05
T cells 17.7 (22%) 3.8 21.3 (26.8) 3.9 p  0.05
CD4 T cells 10.8 (13.4%) 2.1 12.2 (15.4%) 2.1 p  0.05
CD8 T cells 5.1 (6.3%) 2.0 7.5 (9.5%) 2.3 p  0.05
plasma cells 1.4 (1.7%) 0.6 1.1 (1.4%) 0.5 p  0.05
Splenocytes of 9-month-old APRIL transgenic mice and age-matched control littermates (n  5) were analyzed for their content. Populations were defined
as follows: B cells (B220, IgM, Thy1.2); T1 (B220, CD23, CD21, IgMhigh); T2 (B220, CD23, CD21high, IgMhigh); mature B cells (B220, CD23, CD21, IgM);
MZ (B220, CD23, CD21high, IgMhigh); B1 (B220, CD23, IgM, CD5); macrophages (Mac3); granulocytes (GR1), dendritic cells (CD11c), T cells (Thy1.2),
CD4 T cells (Thy1.2, CD4); CD8 T cells (Thy1.2, CD8); plasma cells (B220low/, CD138, CD3).
* n  3
Figure 3. Histological examination of lymphoid
tissues from 9- to 12-month-old APRIL-Tg mice
and age-matched littermates
A: Hematoxylin/eosin (HE)-stained spleen sec-
tions from littermate and APRIL-Tg mice. Data
are representative of six mice displaying splenic
disorganization and cellular infiltration in the
capsule.
B: Histological analysis of an mLN from a control
mouse and an enlarged mLN from an APRIL-Tg
mouse. CD3 T cell and B220 B cell distribution
is shown. Data are representative of six mice an-
alyzed.
C: HE-stained tissue sections of an advanced
mLN tumor. Boxed area is enlarged to show cell
infiltration into the subcapsular sinus. Dotted line
indicates the subcapsular area.
D: B220 cell distribution in PP from a 12-month-
old APRIL-Tg mouse with an advanced PP tumor.
Boxed area is enlarged to show B220 cell infil-
tration into the adjacent mucosal layer (M).
Groups of at least 10 APRIL-Tg or control mice
were analyzed.
E: Forward scatter analysis of cells derived from
hyperplasic spleen, mLN, and PP, representative
of 30 mice analyzed.
F: CD4 and CD8 T cells and B220 B cells of
an enlarged mLN of an APRIL-Tg mouse and an
age-matched littermate were stained for activa-
tion markers CD44 and CD62L (T cell) and CD80
and CD86 (B cell).
G: Analysis of lymphocytes of an enlarged mLN
of an APRIL-Tg mouse using anti-Ki-67 or an iso-
type-matched control to determine mitotic ac-
tivity.
F and G include representative images obtained
by analyzing enlarged mesenteric lymph nodes
of one APRIL-Tg mice.
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Figure 4. B-1 cell accumulation in APRIL Tg mice
during aging
A: No increase in mitotic activity (anti-Ki-67) is
observed in 9-month-old APRIL-Tg mouse perito-
neal B-1 cells compared to those of littermates.
B: In vitro survival of B-1 cells isolated from perito-
neal cells, measured by PI exclusion. Data are
representative of three independent experi-
ments.
C: B-1 cells display increased in vivo survival in
APRIL-Tg mice. SJL (CD45.1) PEC cells were de-
pleted of T cells and injected i.p. into 8-month-
old APRIL-Tg mice or age-matched littermates
(both CD45.2). Survival of injected cells was de-
termined after 10 days using the congenic differ-
ence (CD45) and compared to the cells that
could be retrieved immediately after injection
(set to 100%). Decrease in cell number was deter-
mined by dividing the number of B-1 or B-2 cells
present at day 10 with the amount of cells pres-
ent at day 0. Five mice per group were analyzed,
and statistical analysis was calculated using
ANOVA.
(Figure 3G). We thus conclude that mLN expansion in APRIL- B220dim, and CD23 B cells (Figure 5B). Although B-1 cells
normally express high levels of IgM, peritoneal B-1 expansionTg mice is due to lymphocyte hyperactivation that leads to
hyperplasia. is accompanied by a downregulation of surface IgM, a possible
sign of an increased activation status (Fagarasan et al., 2000).APRIL was previously shown to induce tumor cell prolifera-
tion in vitro and in vivo (Hahne et al., 1998; Rennert et al., Intriguingly, the CD5, CD19, IgMdim, B220dim, and CD23 B
cells present in the hyperplasic mLN are phenotypically identical2000). We nonetheless found no evidence of increased B-1 cell
proliferation in older APRIL-Tg mice, as measured by Ki-67 to the expanding B-1 cells in the peritoneum (Figure 5A). This
suggests that peritoneal B-1 cells accumulate gradually in theexpression (Figure 4A). In addition to stimulating proliferation,
APRIL can induce lymphoid and glioma tumor cell survival (De- mLN of APRIL-Tg mice and are instrumental in initiating mLN
hyperplasia.shayes et al., 2004; Hahne et al., 1998; Stein et al., 2002; Yu
et al., 2000). We therefore analyzed the survival capacity of To confirm this hypothesis, we tested whether B-1 cells
from APRIL-Tg mice with clear signs of mLN activation couldperitoneal B-1 cells from APRIL-Tg and control mice. Approxi-
mately 50% of B-1 cells from littermates had died by 10 days transfer the mLN hyperplasic phenotype to 8-week-old non-Tg
mice that contain a congenic difference (SJL). Six mice receivedin vitro culture, whereas those from APRIL-Tg mice survived
far more efficiently (Figure 4B). This suggests that a survival intraperitoneal injections of purified B-1 cells from hyperplasic
mLN. Six weeks later, four of these mice appeared normal (Fig-advantage permits these cells to expand in vivo. In agreement,
injection of peritoneal cells from congenic C57BL/6 SJL mice ure 5C), whereas two mice showed massive mLN activation, as
indicated by T and B cell activation markers (Figure 5C) andinto the peritoneal cavity of APRIL-Tg and littermates revealed
that B-1 cells survive 3-fold better when exposed to APRIL Ki-67 staining (not shown). Importantly, we could only detect
around 1%–2% CD45.2 cells in the affected mLN, indicating(Figure 4C). This survival is specific for B-1 cells, as B-2 B cells
do not display a survival advantage in APRIL-Tg mice (Figure that the active B and T cells were not derived from the injected
cells, but were endogenous SJL cells. The difference between4C). Moreover, in vitro treatment with death agonists such as
VP-16, doxorubicin, and staurosporin displayed an increased responding and nonresponding mice could be the result of
slower tumor growth onset in the latter; alternatively, mouse-survival capacity of transgenic B-1 B cells in comparison to the
ones of control mice. As APRIL binds specifically and with high intrinsic factors may be decisive in hyperplasia development. It
is nonetheless evident that these B-1 cells can induce the mLNaffinity to B-1 cells (not shown), it is likely that this survival
capacity is mediated directly by APRIL. hyperplasic phenotype in young non-Tg animals, indicating that
the peritoneal B-1 cells are instrumental in the lymph nodeAs only 40% of the older mice show mLN hyperplasia, we
reevaluated their PEC and found that B-1 cell expansion was hyperplasia observed.
As described, some older APRIL-Tg mice showed splenicmost pronounced in APRIL-Tg mice with hyperplasia (Figure
5A). These B-1 cells were CD5 and therefore of the B-1a sub- alteration (Figures 2F and 3A), suggesting that the hyperplasic
phenotype is not confined to mLN and PP, but spreads through-type, although they showed decreased IgM and B220 expres-
sion, probably due to increased activation (Figure 5A). Migration out the lymphoid system. This became more evident in several
18-month-old APRIL-Tg mice analyzed, which displayed a moreof peritoneal B-1 cells to mLN was reported to require a greater
activation level than that needed for self-renewal (Fagarasan et dramatic expansion of B-1 cells in the mLN (up to 107 B-1a
cells), as well as greatly enlarged spleens (8-fold). In theseal., 2000). Concurring with B-1 cell migratory capacity, enlarged
mLN revealed a striking increase in CD5, CD19, IgMdim, mice, approximately 50% of splenocytes were CD5, IgMdim,
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Figure 5. Accumulation of B1 cells in mLN and infiltration of B-1 cells into nonlymphoid tissue in older APRIL Tg mice
A: B-1 cell expansion is most pronounced in APRIL-Tg mice showing mLN and PP enlargement. Representative data are shown for 10 mice analyzed.
B: Increased numbers of B-1 cells are detected in enlarged mLN. B-1 cells (boxed) are IgMlowCD5dim and CD23B220dim.
C: Transfer of pure peritoneal B-1 cells from an APRIL-Tg mouse with significant B-1 expansion results in mLN lymphocyte activation. Left panels show a
nonactivated mLN, right panels show an activated mLN.
D: B-1 cell infiltration in enlarged spleen of two separate APRIL-Tg mice (18-month-old). A spleen from an age-matched littermate is used as a control.
Percentages indicate B-1 cells in boxed areas (IgMlowCD5dim and CD23B220dim).
E: HE and anti-B220 staining of infiltrating lymphocytes in kidney sections from an 18-month-old APRIL-Tg mouse. Multiple areas of cell infiltration from blood
vessels are detected. Sections from control mice show no cell infiltration and reveal normal tissue architecture.
F: Kidney infiltrating cells lack CD3 expression (top), but a fraction of the cells are CD5 (bottom). An enlargement is shown of an area containing infiltration
of B220 cells. Several sites of B220 cell infiltration were detected in the kidney; a representative image is shown.
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B220dim, CD23 (Figure 5D), and CD19 and CD3 (not shown), by initially nonmalignant lymphoid abnormalities that can pro-
gress to malignant lymphoma (Frederickson and Harris, 2000).indicating massive B-1a cell expansion in the spleen. Moreover,
clear macroscopic alterations were evident in kidney and liver Further analysis is needed to understand the mechanisms by
which B-1 cells induce lymphocyte hyperplasia in mLN and PP(not shown) in these mice, and immunohistochemical analysis
of these nonlymphoid organs showed extensive lymphoid cell in older APRIL-Tg mice. Differences in B and T cell composition
do not account for the hyperplasia observed in older APRIL-Tginfiltration (Figure 5E and not shown). Infiltrating cells were
B220, CD3, TCR	 (Figure 5E and not shown), indicating mouse mLN, which appears to be the consequence of a mutual
activation loop between B and T cells. B-1 cells present inthat infiltrating cells are B cells and not T cells. Most of the
B220, CD3, TCR	 cells appeared to be CD5, though not hyperplasic mLN express large amounts of IL-10 and TNF	 (not
shown), which could be involved in the activation of residentall of them (Figure 5F). To analyze whether this is due to the
presence of a mixed population of cells or due to the efficiency mLN lymphocytes (O’Garra and Howard, 1992). In fact, a recent
study in NZB IL-10 knockout mice has well documented theof the antibody in immunohistochemistry, we decided to further
identify the cells present in the infiltrate. For this, we made use crucial role for IL-10 in the development and expansion of malig-
nant B-1 cells (Czarneski et al., 2004). Moreover, an increasedof a novel technique that allows cells to be isolated from snap-
frozen tissue sections and to be processed for FACS staining CD4:CD8 T cell ratio was detected in PP and mLN of older
APRIL-Tg mice, possibly the result of such an activation loop.(Baeten et al., 2002). This analysis revealed that the majority of
lymphoid cells (85%) present in the kidney, which includes the In contrast, the CD4:CD8 T cell ratio was decreased in the
blood of tumor-bearing APRIL-Tg mice (not shown). It is note-blood vessels, are CD5 and CD3, while only a minority are
T cell (7% CD5/CD3) or do not stain for CD5 or CD3 (8%) worthy that inverse CD4:CD8 T cell ratio evolution has also
been observed in lymphoid organs and blood of B-CLL patients(Figure 5G). We therefore conclude that the cells infiltrating the
kidney are B220 (Figure 5E), CD5 (Figures 5F and 5G), and (Terstappen et al., 1990).
We observed an expansion of peritoneal B-1 cells in 4-month-for the larger part CD3 (Figures 5F and 5G), and are thus
malignant B-1a tumor cells. In summary, the B-1 cell population old APRIL-Tg mice that was more pronounced in 9- to 12-month-
old animals. About 40% of Tg mice at this age displayed expan-expansion observed in aging Tg mice leads initially to tumor
formation within the lymphoid system; these cells eventually sion of T and B cell populations in mLN or PP. We propose that
APRIL is a supporting factor for B-1 cell stimulation, and thatmetastasize and infiltrate nonlymphoid tissues such as mucosa,
kidney, and liver. its overexpression results in increased B-1 cell survival and
activity. Although APRIL can support B cell activation in vitro,B-1 cells appear to arise mainly, but not exclusively, during
fetal/neonatal B cell lymphopoiesis (Stein et al., 2002). In con- an in vivo effect on B cells has not yet been described (Mackay
et al., 2002). In contrast, BLyS, the closest homolog of APRIL,trast to B-2 cells, B-1 cells have self-renewal capacity and thus
maintain normal numbers during adulthood (Potter and Melch- supports B cell survival in vivo and in vitro (Mackay et al., 2002).
It is highly unlikely, though, that the effects observed in APRIL-ers, 2000). Several reports suggest that B-1 cells are susceptible
to oncogenic mutation and progression to B cell neoplasia (Pot- Tg mice are mediated by BLyS, as no increases in BLyS mRNA
are observed in the spleen (not shown). Moreover, the APRIL-ter and Melchers, 2000). Inherent or induced differences in indi-
vidual B-1 cell clone division rates can lead in time to the devel- Tg mice do not display typical signs of BLyS expression, such
as splenic B cell expansion (Mackay et al., 2002) (Table 1).opment and expansion of dominant clones within the B-1 cell
population (Stall et al., 1988), which are detectable in older mRNA for two the known APRIL receptors, TACI and BCMA,
is expressed at comparable levels in all B cell subsets (notanimals (18 months) of most, if not all, mouse strains (Stall et
al., 1988). These clonal populations arise in the peritoneal cavity shown). Nevertheless, APRIL binds with much higher affinity to
B-1 B cells as compared to the splenic subsets (not shown),and eventually invade lymphoid tissue (Stall et al., 1988). We
observed B-1 cell expansion in 4- to 5-month-old APRIL-Tg suggesting the possible involvement of a third APRIL receptor.
Though the receptor(s) mediating the stimulatory effect of APRILmice, whereas B-1 cell numbers in 6-week-old Tg mice were
similar to those of age-matched littermates (Stein et al., 2002). on B-1 cells remains to be identified, it is evident that APRIL
imposes an in vivo survival advantage on PEC B-1 cells, whileOur findings suggest that APRIL promotes and accelerates age-
related B-1 cell expansion, which appears to be a result of B-2 cells are not affected (Figure 4). How this survival advantage
leads to B-1 cell accumulation in mLN and lymphoid organincreased survival capacity rather than increased mitotic activ-
ity. This mirrors the status of human B-CLL cells, which are hyperplasia is still an enigma. We believe that activation of B-1
cells by antigenic stimulation would allow these cells to migratecharacterized by low proliferative activity and progressive accu-
mulation of clonal B lymphocytes blocked in the G0/G1 cell cycle to the mLN. In line with this hypothesis is the observation that
NP-LPS, a thymus-independent type 1 antigen that is knownphases (Andreeff et al., 1980).
The highest incidence of tumor formation in APRIL-Tg mice to activate B-1 cells, increases the number of B-1 cells present
in the mLN significantly even at 6 weeks after NP-LPS adminis-was observed in mLN and PP, and less frequently in spleen.
The mLN is considered to be the first lymphoid organ affected tration (not shown). The accumulation of B-1 cells in the mLN
G: Kidney-infiltrating cells are mainly CD5 positive and are not T cells. 30 
m cryosections of the infiltrated kidney shown in E and F were selected on the
basis of infiltration. Cells were retrieved for FACS analysis and stained for H-2Kb, CD5, and CD3. H-2Kb expression was used to select lymphocytes, and CD5
and CD3 expression was measured to determine the incidence of B-1a cells in the infiltrated kidney. Shown is the CD5 expression in the three H-2Kb-high
lymphocytes populations visible in the infiltrated kidney as determined by CD3 and CD5 staining. Percentages indicate the relative contribution of the
population to the total lymphocytes present in the kidney.
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well as Ki-67 kits, were purchased from BD Pharmingen and used accordingmay affect the lymphoid environment by producing cytokines
to manufacturer’s specifications.and could thus lead to mLN hyperplasia. All mice that display
spleen and kidney infiltration display mLN hyperplasia as well,
ELISAsuggesting that it is a prerequisite for the eventual malignant
APRIL serum immunoglobulin was quantified by standard ELISA techniques
phenotype. It is very likely that this malignant transformation using BCMA-FC (1 
g/ml; Sigma-Aldrich) for capture and anti-APRIL anti-
requires a second hit, similar to what has been suggested for body (1 
g/ml) (Lopez-Fraga et al., 2001; Pradet-Balade et al., 2002; Stein
the TCL1-induced lymphoma formation (Virgilio et al., 1998). et al., 2002) combined with on human IgG absorbed 	-rabbit-peroxidase
secondary antibody (Jackson laboratory) for detection. Specificity of APRILAge-related B-1 cell neoplasia in mice has been compared
detection was verified by including wells coated with an irrelevant Fc-hybridto human B-CLL, as both diseases develop during aging as a
protein as control. Serum dilutions used for quantification were within theresult of slowly expanding CD5 B cell populations. The NZW
linear absorbance range at 492 nm, and recombinant APRIL (R&D Systems)and TCL1 Tg mouse models for B-CLL show B-1 cell expansion
was used for standardization. Sera tested included samples from untreated
as a result of a survival benefit (Bichi et al., 2002; Hamano et and treated B-CLL patients; this revealed no significant difference between
al., 1998). By analogy with our data for APRIL-Tg mice, the these two groups. The use of B-CLL samples for RNA analysis and sera
TCL1 Tg mice show initial gradual increases in the peritoneal protein detection was approved by the Medical Ethical Committee of the
Amsterdam Medical Center (AMC).CD5 B cell population; later stages are characterized by
Serum IgA levels were determined using an ELISA kit (BD/PharMingen)spreading of these cells to lymphoid organs. A role for B-1 cell
according to manufacturer’s instructions.tumor formation in humans is persuasively supported by the
detection of APRIL overexpression in a large fraction of B-CLL
Reverse transcriptase and PCR
tumors tested and of increased APRIL serum levels in these B-CLL samples were directly subjected to RNA isolation using the Qiagen
patients. Results from our APRIL-Tg mice strongly suggest a RNeasy isolation procedure. Total RNA (2 
g) was reverse transcribed using
role for this TNF ligand in B-1 cell tumor development. Increased AMV-reverse transcriptase, then analyzed for APRIL expression by PCR
using CCAGCCTCATCTCCTTTCTTGC as forward and TCACAGTTTCACAAAPRIL expression in B-CLL patients indicates that APRIL trans-
ACCCCAGG as reverse primer.  actin served as an internal control andgenics are an appropriate mouse model for study of the human
was amplified using GGCATCGTGATGGACTCCG as forward and GCTGGAdisease.
AGGTGGACAGCGA as reverse primer. Three B-CLL samples were chosenAPRIL-Tg mice express the transgene in T cells, which re-
and purified to homogeneity by negative selection for CD14 and CD3 (the
sults in elevated APRIL serum levels. APRIL thus acts systemi- impurities detected in these samples) using CD14-PE and CD3-PE (BD
cally in the Tg mice (Stein et al., 2002), affecting B-1 cell survival. PharMingen) and anti-PE magnetic beads (Miltenyi Biotech). Control B cell
Since APRIL acts as a secreted factor, elevated APRIL levels samples were isolated from pooled buffy coats (Bloodbank Leiden, 5
donors) by positive selection with CD19-FITC (BD PharMingen) and anti-may also be the result of production by non-tumor cells. It is
FITC magnetic beads (Miltenyi Biotech). After purification of normal B cellsthus reasonable to assume that determination of APRIL mRNA
or B-CLL samples, RNA was immediately isolated as above.levels in patient tumor cells may underestimate true APRIL
involvement in B-CLL. It may be of interest to determine APRIL
In vitro and in vivo survivalproduction by so-called nurse-like cells, which are described
Peritoneal cells were depleted of T cells using CD3-FITC staining and mag-
to supply B-CLL tumor cells with a survival factor in vitro, and netic anti-FITC beads, then cultured in vitro (105 cells/well). Cells were col-
reported to exist in B-CLL patients as well (Tsukada et al., 2002). lected at different time points, stained for CD43 to discriminate B-1 from
The increased APRIL mRNA and serum levels in B-CLL patients, B-2 B cells, and cell death measured using PI-exclusion by FACS analysis.
Percentages are calculated as number of CD43PI/total number of CD43combined with the B-1-associated tumorigenesis in APRIL-Tg
cells.mice, substantiate the involvement of this cytokine in B-CLL
For in vivo survival assays, peritoneal cells were isolated from C56BL/6and may yield new therapeutic strategies aimed at preventing
SJL mice, which contain a congenic marker (CD45.1) that allows their detec-APRIL-induced tumor cell survival.
tion in the C56BL/6 background of the transgenic strain. SJL PEC cells were
depleted of T cells using Dynal beads and subsequently injected intraperito-Experimental procedures
neally into 8-month-old littermates and APRIL-Tg (mice containing detect-
able levels of APRIL in their serum [Stein et al., 2002]). PEC cells of a groupMice
of recipient mice were analyzed immediately after injection to determine theGeneration of APRIL-Tg mouse lines 3919 and 2968 has been described
amount of B-1 and B-2 cells retrievable from the PEC, and 10 days later(Stein et al., 2002). Mice used in these experiments had been backcrossed
from a separate group of 5 mice to determine the in vivo survival. B-1 andat least seven times onto the C57BL/6 background. Mice were housed under
B-2 cells were identified with CD43 and IgD and the fold decrease in cellspecific pathogen-free conditions at the CNB (Madrid) or the CPV-LUMC
number was determined by dividing the absolute number present at day 10(Leiden). Animal experiments were performed in compliance with national
by the absolute number present at day 0.and institutional guidelines. Experiments were approved by the animal ethical
committee of the Leiden University and authorized by the respective French
Histopathologyauthorities (De´partementale des service ve´te´rinaire de Prefecture De l’He-
Lymphoid organs were formalin-fixed (5%) and paraffin embedded; deparaf-rault), permit number B 34-172-16.
finized sections (4 
m) were hematoxylin/eosin stained. For immunostaining,
sections were deparaffinized and treated with distilled water containing 3%Flow cytometric analysis
H2O2 in 70% methanol, followed by microwave treatment in 10 mM sodiumCells were stained with appropriate antibodies and analyzed on a Becton-
citrate buffer, blocked using a biotin blocking kit (Dako, Glostrup, Denmark),Dickinson flow cytometer. Freshly prepared lymphocytes were resuspended
and incubated with 20% normal goat serum. Sections were incubated within FACS buffer (1% BSA, 0.05% sodium azide in PBS). Labeled anti-mouse -
biotin-anti-B220 (Southern Biotechnology) antibody (overnight, 4C) and de-H-2Kb (AF6-88.5), -CD3 (145-2C11), -CD4 (L3T4), -CD8 (Ly-2), CD45R/B220
veloped with the StrepABComplex/HRP kit (Dako). Phosphatase activity(RA3-6B2), -IgD (11-26c.2a), -IgM (R6-60.2), CD69 (H1.2F3), CD62L (Mel-
was developed using BCIP/NBT substrate system (Dako) and analyzed by14), -CD44 (IM7), -CD45RB (16A), -CD23 (B3B4), -CD24 (HSA, 30F1), -CD43
conventional microscopy. Tissue sections were analyzed by Leica Q-Win(1B11), -CD21 (7G6), CD5 (53-7.3), CD80 (16-10A1), CD86 (GL1), -Mac3 (M3/
84), -Ly6C (Gr1) (RB6-8C5), -CD11c (HL3), and -CD138 (281-2) antibodies, as software to determine Peyer’s patch size.
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Castigli, E., Scott, S., Dedeoglu, F., Bryce, P., Jabara, H., Bhan, A.K., Mizo-Immunofluorescence
guchi, E., and Geha, R.S. (2004). Impaired IgA class switching in APRIL-Kidneys were snap-frozen in liquid nitrogen, and 5 
m sections were stained
deficient mice. Proc. Natl. Acad. Sci. USA 101, 3903–3908.with hematoxylin/eosin and for B220, CD5, and CD3 (BD Pharmingen). De-
tection was direct with FITC-label (B220) or indirect with streptavidin-conju- Czarneski, J., Lin, Y.C., Chong, S., McCarthy, B., Fernandes, H., Parker, G.,
gated-Alexa fluor 546 (Molecular Probes). Background staining was blocked Mansour, A., Huppi, K., Marti, G.E., and Raveche, E. (2004). Studies in NZB
using the endogenous biotin blocking kit (Molecular Probes). Normal spleen IL-10 knockout mice of the requirement of IL-10 for progression of B-cell
served as a positive control for all antibodies used. Isolation of lymphoid lymphoma. Leukemia 18, 597–606.
cells from snap-frozen tissue for FACS analysis was performed as described
Deshayes, F., Lapree, G., Portier, A., Richard, Y., Pencalet, P., Mahieu-by Baeten et al. (2002). In brief, 30 
m sections were fixed in paraformalde-
Caputo, D., Horellou, P., and Tsapis, A. (2004). Abnormal production ofhyde (1%) and collagenase-treated for 30 min (5 mg/ml). Afterward, cells
the TNF-homologue APRIL increases the proliferation of human malignantwere stained with anti-H-2Kb, -CD3, and -CD5 to determine the identity of
glioblastoma cell lines via a specific receptor. Oncogene 23, 3005–3012.infiltrating cells.
Fagarasan, S., Watanabe, N., and Honjo, T. (2000). Generation, expansion,
Adoptive transfer of peritoneal B-1 cells migration and activation of mouse B1 cells. Immunol. Rev. 176, 205–215.
Peritoneal cells from an advanced stage tumor-bearing mouse were cultured
Frederickson, T., and Harris, A. (2000). Atlas of mouse hematopathology.overnight to deplete peritoneal macrophages by adherence; the resulting
(Amsterdam: Harwood Academic Publishers).culture was95% B-1 cells. Cells (107) were subsequently injected intraperi-
toneally into 8-week-old C57BL/6 mice. After 6 weeks, mice were sacrificed Hahne, M., Kataoka, T., Schroter, M., Hofmann, K., Irmler, M., Bodmer, J.L.,
and mLN were isolated and analyzed for CD4, CD8 T cell and B220 B Schneider, P., Bornand, T., Holler, N., French, L.E., et al. (1998). APRIL, a
cell activation using CD44, CD62L, CD80, and CD86. new ligand of the tumor necrosis factor family, stimulates tumor cell growth.
J. Exp. Med. 188, 1185–1190.
Statistical analysis
Hamano, Y., Hirose, S., Ida, A., Abe, M., Zhang, D., Kodera, S., Jiang, Y.,
The statistical significance of the data was determined using ANOVA analysis Shirai, J., Miura, Y., Nishimura, H., and Shirai, T. (1998). Susceptibility alleles
of variance. P values  0.05 are considered nonsignificant, p values  0.05 for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell
as significant, p values  0.01 as very significant, p values  0.0001 as chronic lymphocytic leukemia in a model of New Zealand white mice. Blood
extremely significant. 92, 3772–3779.
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